Key result
Apixaban was associated with significantly lower risks of bleeding requiring hospitalization (HR 0.43), all-cause death (HR 0.61), and recurrent VTE (HR 0.67) compared to vitamin K antagonists.
Why the study?
Clinical trials show DOACs are noninferior and safer than conventional therapy for VTE, but their real-world effectiveness and safety needed comparison.
Do direct oral anticoagulants (apixaban or rivaroxaban) improve safety and effectiveness compared to vitamin K antagonists in adult patients hospitalized for acute VTE?
Cohort (n=58,137)
Do direct oral anticoagulants (apixaban or rivaroxaban) improve safety and effectiveness compared to vitamin K antagonists in adult patients hospitalized for acute VTE?
Hazard Ratio: 0.43 (95% CI 0.32–0.59)
Absolute Event Rate: 0.83% vs 1.64%
In a real-world nationwide cohort, apixaban demonstrated superior safety and effectiveness compared to VKAs for acute VTE treatment, and both apixaban and rivaroxaban were associated with lower all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Adds real-world data on DOACs for VTE; leaves open generalizability and long-term outcomes.
Bertoletti et al. (2022) conducted a cohort in Acute Venous Thromboembolism (n=58,137). Apixaban vs. Vitamin K antagonists (VKAs) was evaluated on Bleeding requiring hospitalization (Apixaban vs VKA) (HR 0.43, 95% CI 0.32-0.59). Apixaban was associated with significantly lower risks of bleeding requiring hospitalization (HR 0.43), all-cause death (HR 0.61), and recurrent VTE (HR 0.67) compared to vitamin K antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: